An officer proposes selling Kiniksa (KNSA) shares, including 97,572 from an option exercise.
Alpha Vantage · Stock Titan · · AI-summarised by FinFlash
Kiniksa Pharmaceuticals International, plc officer Ross Moat has proposed selling 103,585 Class A ordinary shares, valued at approximately $9.75 million, through Charles Schwab & Co., Inc. The proposed sale, with an approximate date of October 30, 2026, includes shares from two restricted stock lapses and a significant portion (97,572 shares) from an employee stock option exercise.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.